{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:16:48Z","timestamp":1777907808549,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Pharmacopsychiatry"],"abstract":"<jats:p>Interactions of EMD 21 657 - a neurotropic drug \u2014 and maprotiline\nwere studied in 40 depressive outpatients. Patients were assigned at random to an experimental\nor a control group. 20 patients of the experimental group received EMD 21 657 (3 X 400\nmg\/day p.o.) in addition to maprotiline (75 mg\/day p.o.) during an initial treatment of 10\ndays. 20 patients of the control group were treated during this period with maprotiline of\nthe same dosage but did not receive EMD 21 657 as co-medication.\nDuring the 10-day period of treatment and observation, subjective information on the\nfirst day of improvement of depressive symptoms and severity of side effects were recorded.\nUnder supplementary treatment with EMD 21 657 the onset of antidepressant action\noccurred sooner than in the control group receiving maprotiline alone. The earlier improvement\nin the experimental group was statistically significant in the target symptom 'obsessive\nrumination' (p &lt; 0.01). Undesirable effects of maprotiline treatment were seldom observed\nor were mild in terms of severity. A decrease in the rate of side effects in the experimental\ngroup could not be shown statistically.<\/jats:p>","DOI":"10.1159\/000468429","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:20:23Z","timestamp":1502472023000},"page":"137-142","source":"Crossref","is-referenced-by-count":0,"title":["Neurotropic Drugs as Co-Medication to Psychotropics"],"prefix":"10.1159","author":[{"given":"B.","family":"Reinhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"P\u00f6ldinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["International Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000468429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:48:47Z","timestamp":1777643327000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000468429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000468429","archive":["Portico"],"relation":{},"ISSN":["0020-8272","2504-2580"],"issn-type":[{"value":"0020-8272","type":"print"},{"value":"2504-2580","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}